<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">383</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2020-19-3-54-60</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The current status of remote diagnosis of von Willebrand disease in children in Russia</article-title><trans-title-group xml:lang="ru"><trans-title>Современные возможности дистанционной диагностики болезни Виллебранда у детей, проживающих на территории Российской Федерации</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5209-2099</contrib-id><name-alternatives><name xml:lang="en"><surname>Poletaev</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Полетаев</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head of the Clinical Hemostasis Laboratory,</p><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>заведующий лабораторией клинического гемостаза,</p><p>117997, Москва, ул. Саморы Машела, 1 </p></bio><email>poletaev_alexandr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7534-3863</contrib-id><name-alternatives><name xml:lang="en"><surname>Seregina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Серегина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4567-1871</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4384-6754</contrib-id><name-alternatives><name xml:lang="en"><surname>Zharkov</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Жарков</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>117997, Moscow, Samory Mashela st., 1</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН Центр теоретических проблем физико-химической фармакологии РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-09-08" publication-format="electronic"><day>08</day><month>09</month><year>2020</year></pub-date><volume>19</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>54</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2020-10-03"><day>03</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-10-03"><day>03</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/383">https://hemoncim.com/jour/article/view/383</self-uri><abstract xml:lang="en"><p>The diagnosis of von Willebrand disease (vWD) in children remains a challenge in many regions of our country. This encouraged the Russian Hemophilia Society to create, in 2019, a special diagnostic programme offering remote diagnosis of vWD to patients in regions. Objectives: An interim evaluation of the effectiveness of the programme for remote diagnosis of vWD in children. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Under this programme, if advised by a hematologist at the place of residence, a patient's peripheral blood was collected, frozen and sent to the Clinical Hemostasis Laboratory at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Over the period from 11.04.2019 to 07.08.2020, we received 72 frozen peripheral blood samples from children under the age of 18 sent from 21 regions of the Russian Federation. Von Willebrand factor (vWF) ristocetin cofactor activity, vWF antigen levels as well as coagulation factor VIII activity were measured. Out of the 72 samples, only one (1.4%) was inadequate. Reduced vWF activity (30–50%) was observed in 16.7% of cases, and another 16.7% of patients had vWF activity &lt; 30%. VWF antigen levels were 30–50 % in 13.9 % of patients and &lt; 30% in 9.7% of cases. Among the patients with vWF activity &lt; 30%, 1 patient (8.3%) had type 1 vWD, 10 patients (83.3%) – type 2 vWD, 1 child (8.3%) – type 3 vWD. Six children (8.3%) demonstrated reduced factor VIII activity while maintaining normal vWF activity and antigen levels. The coagulation factor VIII activity/vWF antigen ratio was decreased in 8 children (11.1%). The vWD remote diagnosis programme has allowed us to detect abnormalities in 30 patients (41.7%), 16.7% of whom demonstrated laboratory features characteristic of vWD. Eighteen children (25%) require further, more comprehensive laboratory testing. This programme has great potential, especially in underpopulated regions where the development of local diagnostic capabilities may not be economically viable.</p></abstract><trans-abstract xml:lang="ru"><p>Диагностические возможности выявления болезни Виллебранда (БВ) у детей ограничены во многих регионах нашей страны. В связи с этим в 2019 г. Всероссийским обществом гемофилии была создана программа, предусматривающая дистанционную диагностику данного заболевания в регионах. Цель исследования: оценить промежуточные результаты функционирования программы дистанционной диагностики БВ у детей. Исследование одобрено независимым этическим комитетом и утверждено решением ученого совета ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России. В рамках программы в соответствии с решением врача-гематолога по месту жительства пациентам проводился отбор периферической крови с последующей заморозкой и транспортировкой в лабораторию клинического гемостаза ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России. За период с 11.04.2019 по 07.08.2020 поступило 72 замороженных образца периферической крови детей в возрасте до 18 лет из 21 региона Российской Федерации. Оценивали концентрацию антигена и ристоцетин-кофакторную активность фактора Виллебранда (ФВ), а также активность фактора свертывания крови VIII. Нарушение пробоподготовки было выявлено в 1 (1,4%) образце. В результате проведенного анализа снижение активности ФВ в пределах 30–50% было выявлено в 16,7% случаев, менее 30% – также в 16,7% случаев, а концентрации антигена ФВ – в 13,9% и 9,7% проб соответственно. Среди пациентов с активностью ФВ менее 30% 1-му типу соответствовал 1 (8,3%) пациент, 2-му типу – 10 (83,3%) человек, 3-му типу – 1 (8,3%) ребенок. Снижение фактора VIII на фоне нормальных значений активности и антигена ФВ было выявлено в 6 (8,3%) случаях, при этом уменьшение отношения активности фактора свертывания крови VIII к антигену ФВ – у 8 (11,1%) детей. Применение программы дистанционной диагностики БВ позволило выявить патологический результат у 30 (41,7%) пациентов, среди которых лабораторная картина, характерная для данного заболевания, была обнаружена в 16,7% случаев, а в повторном уточняющем обследовании с применением расширенной панели лабораторных исследований нуждаются 18 (25%) человек. Данная программа имеет большой потенциал, особенно применительно к малонаселенным регионам страны, в которых налаживание региональной диагностики может быть экономически нецелесообразно.</p></trans-abstract><kwd-group xml:lang="en"><kwd>von Willebrand disease</kwd><kwd>children</kwd><kwd>bleeding</kwd><kwd>factor</kwd><kwd>diagnosis</kwd><kwd>hemorrhagic syndrome</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Виллебранда</kwd><kwd>дети</kwd><kwd>кровотечение</kwd><kwd>фактор</kwd><kwd>диагностика</kwd><kwd>геморрагический синдром</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Коллектив авторов выражает благодарность президенту Всероссийского общества гемофилии Юрию Александровичу Жулеву и координатору диагностического проекта по болезни Виллебранда Марине Викторовне Дубининой.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Руководство по гематологии в 3 т. Под ред. Воробьева А.И. М.: Ньюдиамед; 2005.</mixed-citation><mixed-citation xml:lang="ru">Руководство по гематологии в 3 т. Под ред. Воробьева А.И. М.: Ньюдиамед; 2005.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Nichols W.L., Hultin M.B., James A.H., Manco-Johnson M.J., Montgomery R.R., Ortel T.L., et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2): 171–232. DOI: 10.1111/j.1365-2516.2007.01643.x</mixed-citation><mixed-citation xml:lang="ru">Nichols W.L., Hultin M.B., James A.H., Manco-Johnson M.J., Montgomery R.R., Ortel T.L., et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2): 171–232. DOI: 10.1111/j.1365-2516.2007.01643.x</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69 (2): 454–9.</mixed-citation><mixed-citation xml:lang="ru">Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69 (2): 454–9.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Sadler J.E., Mannucci P.M., Berntorp E., Bochkov N., Boulyjenkov V., Ginsburg D., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84 (2): 160–74.</mixed-citation><mixed-citation xml:lang="ru">Sadler J.E., Mannucci P.M., Berntorp E., Bochkov N., Boulyjenkov V., Ginsburg D., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84 (2): 160–74.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Sukhu K., Poovalingam V., Mahomed R., Giangrande P.L. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003; 25 (4): 247–9. DOI: 10.1046/j.1365-2257.2003.00523.x</mixed-citation><mixed-citation xml:lang="ru">Sukhu K., Poovalingam V., Mahomed R., Giangrande P.L. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003; 25 (4): 247–9. DOI: 10.1046/j.1365-2257.2003.00523.x</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Timm A., Fahrenkrug J., Jørgensen H.L., Sennels H.P., Goetze J.P. Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations Haemotology 2014; 93 (1): 48–53. DOI: 10.1111/ejh.12298</mixed-citation><mixed-citation xml:lang="ru">Timm A., Fahrenkrug J., Jørgensen H.L., Sennels H.P., Goetze J.P. Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations Haemotology 2014; 93 (1): 48–53. DOI: 10.1111/ejh.12298</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Knol H.M., Kemperman R.F.J., Kluin-Nelemans H.C., Mulder A.B., Meijer K. Haemostatic variables during normal menstrual cycle. A systematic review Thrombosis and Haemostasis 2012; 107 (1): 22–9. DOI: 10.1160/TH11-07-0481</mixed-citation><mixed-citation xml:lang="ru">Knol H.M., Kemperman R.F.J., Kluin-Nelemans H.C., Mulder A.B., Meijer K. Haemostatic variables during normal menstrual cycle. A systematic review Thrombosis and Haemostasis 2012; 107 (1): 22–9. DOI: 10.1160/TH11-07-0481</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Karl C Desch. Regulation of plasma von Willebrand factor. F1000Res 2018; 7: 96. DOI: 10.12688/f1000research.13056.1</mixed-citation><mixed-citation xml:lang="ru">Karl C Desch. Regulation of plasma von Willebrand factor. F1000Res 2018; 7: 96. DOI: 10.12688/f1000research.13056.1</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Werner E.J., Broxson E.H., Tucker E.L., Giroux D.S., Shults J., Abshire T.C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123 (6): 893–8. DOI: 10.1016/s0022-3476(05)80384-1</mixed-citation><mixed-citation xml:lang="ru">Werner E.J., Broxson E.H., Tucker E.L., Giroux D.S., Shults J., Abshire T.C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123 (6): 893–8. DOI: 10.1016/s0022-3476(05)80384-1</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Андреева Т.А., Климова Н.И., Тарасова И.С., Лаврухин Д.Б., Чернов В.М. Состояние специализированной помощи детям и взрослым с болезнью Виллебранда в РФ (по данным анкетирования главных гематологов). Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2013; 12 (1): 5–12.</mixed-citation><mixed-citation xml:lang="ru">Андреева Т.А., Климова Н.И., Тарасова И.С., Лаврухин Д.Б., Чернов В.М. Состояние специализированной помощи детям и взрослым с болезнью Виллебранда в РФ (по данным анкетирования главных гематологов). Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2013; 12 (1): 5–12.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Collection, Transport, and Processing of Blood Speciments for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; CLSI Approved Guideline. 5th еd. 2008.</mixed-citation><mixed-citation xml:lang="ru">Collection, Transport, and Processing of Blood Speciments for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; CLSI Approved Guideline. 5th еd. 2008.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Oliver S., Lau K.K.E., Chapman K., Favaloro E.J. Laboratory Testing for Von Willebrand Factor Multimers. Methods Mol Biol 2017; 1646: 495–511. DOI: 10.1007/978-1-4939-7196-1-36</mixed-citation><mixed-citation xml:lang="ru">Oliver S., Lau K.K.E., Chapman K., Favaloro E.J. Laboratory Testing for Von Willebrand Factor Multimers. Methods Mol Biol 2017; 1646: 495–511. DOI: 10.1007/978-1-4939-7196-1-36</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Румянцев А.Г., Масчан А.А., Вдовин В.В., Свирин П.В. Федеральные клинические рекомендации по диагностике и лечению детей с гемофилией А, гемофилией В и болезнью Виллебранда. 2015.</mixed-citation><mixed-citation xml:lang="ru">Румянцев А.Г., Масчан А.А., Вдовин В.В., Свирин П.В. Федеральные клинические рекомендации по диагностике и лечению детей с гемофилией А, гемофилией В и болезнью Виллебранда. 2015.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Laffan M.A., Lester W., O’Donnell J.S., Will A., Tait R.C., Goodeve A., et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Hematology. Br J Haematol. 2014; 167 (4): 453–65. DOI: 10.1111/bjh.13064</mixed-citation><mixed-citation xml:lang="ru">Laffan M.A., Lester W., O’Donnell J.S., Will A., Tait R.C., Goodeve A., et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Hematology. Br J Haematol. 2014; 167 (4): 453–65. DOI: 10.1111/bjh.13064</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Favaloro E.J., Bonar R.A., Meiring M., Duncan E., Mohammed S., Sioufi J. et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (2): 393–403. DOI: 10.1016/j.thromres.2014.05.020</mixed-citation><mixed-citation xml:lang="ru">Favaloro E.J., Bonar R.A., Meiring M., Duncan E., Mohammed S., Sioufi J. et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (2): 393–403. DOI: 10.1016/j.thromres.2014.05.020</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Bykowska K., Ceglarek B. Clinical significance of slightly reduced von Willebrand factor activity. Pol Arch Intern Med 2020; 130 (3): 225–31. DOI: 10.20452/pamw.15162</mixed-citation><mixed-citation xml:lang="ru">Bykowska K., Ceglarek B. Clinical significance of slightly reduced von Willebrand factor activity. Pol Arch Intern Med 2020; 130 (3): 225–31. DOI: 10.20452/pamw.15162</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Rosenberg J.B., Greengard J.S., Montgomery R.R. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20 (12): 2689–95. DOI: 10.1161/01.atv.20.12.2689</mixed-citation><mixed-citation xml:lang="ru">Rosenberg J.B., Greengard J.S., Montgomery R.R. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20 (12): 2689–95. DOI: 10.1161/01.atv.20.12.2689</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Lillicrap D., Poon M.C., Walker I., Xie F., Schwartz B.A., Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ Humate P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87 (2): 224–30.</mixed-citation><mixed-citation xml:lang="ru">Lillicrap D., Poon M.C., Walker I., Xie F., Schwartz B.A., Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ Humate P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87 (2): 224–30.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Berntorp E., Abshire T., vWD Steering Committee. The von Willebrand disease prophylaxis network (VWD PN): exploring a treatment concept. Thromb Res 2006; 118 Suppl 1: S19–22. DOI: 10.1016/j.thromres.2006.01.016</mixed-citation><mixed-citation xml:lang="ru">Berntorp E., Abshire T., vWD Steering Committee. The von Willebrand disease prophylaxis network (VWD PN): exploring a treatment concept. Thromb Res 2006; 118 Suppl 1: S19–22. DOI: 10.1016/j.thromres.2006.01.016</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118 Suppl 1: S9–11. DOI: 10.1016/j.thromres.2006.01.021</mixed-citation><mixed-citation xml:lang="ru">Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118 Suppl 1: S9–11. DOI: 10.1016/j.thromres.2006.01.021</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res 2011; 127 Suppl 1: S14–7. DOI: 10.1016/j.thromres.2010.10.005</mixed-citation><mixed-citation xml:lang="ru">Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res 2011; 127 Suppl 1: S14–7. DOI: 10.1016/j.thromres.2010.10.005</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Halimeh S., Krumpel A., Rott H., Bogdanova N., Budde U., Manner D., et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost 2011; 105 (4): 597–604. DOI: 10.1160/TH10-09-0616</mixed-citation><mixed-citation xml:lang="ru">Halimeh S., Krumpel A., Rott H., Bogdanova N., Budde U., Manner D., et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost 2011; 105 (4): 597–604. DOI: 10.1160/TH10-09-0616</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Abshire T.C., Federici A.B., Alvárez M.T., Bowen J., Carcao M.D., Cox Gill J., et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19 (1): 76–81. DOI: 10.1111/j.1365-2516.2012.02916.x</mixed-citation><mixed-citation xml:lang="ru">Abshire T.C., Federici A.B., Alvárez M.T., Bowen J., Carcao M.D., Cox Gill J., et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19 (1): 76–81. DOI: 10.1111/j.1365-2516.2012.02916.x</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Federici A., James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematologica 2012; 128 (2): 88–99. doi: 10.1159/000338208</mixed-citation><mixed-citation xml:lang="ru">Federici A., James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematologica 2012; 128 (2): 88–99. doi: 10.1159/000338208</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Miesbach W., Krekeler S., Wolf Z., Seifried E. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res 2015; 135 (3): 479–84. DOI: 10.1016/j.thromres.2014.12.017</mixed-citation><mixed-citation xml:lang="ru">Miesbach W., Krekeler S., Wolf Z., Seifried E. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res 2015; 135 (3): 479–84. DOI: 10.1016/j.thromres.2014.12.017</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Federici A., Castaman G., Franchini M., Morfini M., Zanon E., Coppola A., et al. Clinical use of Haemate P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients. Haematologica 2007; 92 (7): 944–51. DOI: 10.3324/haematol.11124</mixed-citation><mixed-citation xml:lang="ru">Federici A., Castaman G., Franchini M., Morfini M., Zanon E., Coppola A., et al. Clinical use of Haemate P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients. Haematologica 2007; 92 (7): 944–51. DOI: 10.3324/haematol.11124</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Budde U., Metzner H.J., Muller H.-G. Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease Semin ThrombHemost 2006; 32 (6): 626– 35. DOI: 10.1055/s-2006-949668</mixed-citation><mixed-citation xml:lang="ru">Budde U., Metzner H.J., Muller H.-G. Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease Semin ThrombHemost 2006; 32 (6): 626– 35. DOI: 10.1055/s-2006-949668</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Metzner H.J., Hermetin P., Cuesta-Linker T., Langner S., Mueller H.G., Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 Suppl 3: 25–32. DOI: 10.1046/j.1365-2516.1998.0040s3025.x</mixed-citation><mixed-citation xml:lang="ru">Metzner H.J., Hermetin P., Cuesta-Linker T., Langner S., Mueller H.G., Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 Suppl 3: 25–32. DOI: 10.1046/j.1365-2516.1998.0040s3025.x</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Kouides P., Wawra-Hehenberger K., Sajan A., Mead H., Simon T. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. Transfusion 2017; 57 (10): 2390–403. DOI: 10.1111/trf.14241</mixed-citation><mixed-citation xml:lang="ru">Kouides P., Wawra-Hehenberger K., Sajan A., Mead H., Simon T. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. Transfusion 2017; 57 (10): 2390–403. DOI: 10.1111/trf.14241</mixed-citation></citation-alternatives></ref></ref-list></back></article>
